Table 3 Open in new tab Univariate...

	ΔCCS-SAF		ΔAFEQT		ΔPCS		ΔMCS
Age	−0.02	0.006	−0.1	0.36	0.04	0.52	−0.20	0.03
Sex (female)	−0.20	0.33	8.90	0.02	−0.30	0.84	1.70	0.45
No. of failed AADs	−0.07	0.95	−0.60	0.68	−0.02	0.97	−1.80	0.06
Hx HTN	−0.10	0.45	−4.70	0.19	1.30	0.41	−2.50	0.23
Hx DM	−0.18	0.62	−7.90	0.20	1.50	0.58	−1.30	0.69
LVEF	−0.10	0.78	0.10	0.52	−0.02	0.85	−0.28	0.07
LVEF < 50%	−0.02	0.96	−9.70	0.24	−3.82	0.31	1.24	0.79
Baseline AFB (h/month)	0.001	0.13	−0.01	0.06	−0.004	0.19	−0.007	0.07
Baseline CHADS₂	0.01	0.87	−2.10	0.21	0.30	0.68	−0.90	0.35
Baseline CHADS-VASc	0.21	0.007	0.38	0.76	0.70	0.18	−0.90	0.19
Baseline CCS-SAF	−0.80	<0.001	4.30	0.006	1.20	0.09	−0.60	0.46
Baseline AFEQT	0.008	0.07	−0.69	<0.001	−0.10	<0.001	−0.05	0.25
Baseline PCS	0.01	0.07	−0.58	<0.001	−0.50	<0.001	0.21	0.01
Baseline MCS	0.009	0.27	−0.44	0.001	0.11	0.06	−0.64	<0.001
AAD at 12 months	0.33	0.15	−8.41	0.02	−3.79	0.03	−4.9	0.02
AAD in blanking period	−0.15	0.51	0.14	0.96	0.01	0.99	−3.30	0.14
Procedure type:
PVAC (platinum + gold) vs. control	0.09	0.40	−2.85	0.43	−4.14	0.01	0.64	0.76
PVAC platinum vs. control	0.16	0.49	−4.11	0.29	−4.45	0.01	0.01	0.99
PVAC gold vs. control	−0.03	0.80	−0.07	0.97	−1.69	0.14	1.12	0.46
PVAC gold vs. platinum	−0.23	0.41	3.95	0.40	1.07	0.62	2.2	0.41
Early recurrence	0.59	0.006	−5.10	0.15	−0.48	0.77	−3.44	0.09
Redo ablation	0.20	0.43	−6.10	0.21`	−6.04	0.01	−4.50	0.12
Complications within 12 months follow-up	1.20	0.003	−5.70	0.40	−5.80	0.06	4.90	0.20
Cardioversion within 12 months follow-up	0.10	0.59	−10.70	0.02	−1.04	0.64	−0.50	0.80
#Cardioversion within 12 months follow-up	0.20	0.34	−9.60	0.009	−0.90	0.50	−0.90	0.60
Recurrence	0.80	<0.001	−9.40	0.008	−4.80	0.003	−2.20	0.26
AFB h/month at 12 months <24	−1.90	<0.001	19.50	<0.001	5.50	0.03	2.08	0.50

ΔCCS-SAF

ΔAFEQT

ΔPCS

ΔMCS

P-value

Unstandardized

Age

−0.02

0.006

−0.1

0.36

0.04

0.52

−0.20

0.03

Sex (female)

−0.20

0.33

8.90

0.02

−0.30

0.84

1.70

0.45

No. of failed AADs

−0.07

0.95

−0.60

0.68

−0.02

0.97

−1.80

0.06

Hx HTN

−0.10

0.45

−4.70

0.19

1.30

0.41

−2.50

0.23

Hx DM

−0.18

0.62

−7.90

0.20

1.50

0.58

−1.30

0.69

LVEF

−0.10

0.78

0.10

0.52

−0.02

0.85

−0.28

0.07

LVEF < 50%

−0.02

0.96

−9.70

0.24

−3.82

0.31

1.24

0.79

Baseline AFB (h/month)

0.001

0.13

−0.01

0.06

−0.004

0.19

−0.007

0.07

Baseline CHADS₂

0.01

0.87

−2.10

0.21

0.30

0.68

−0.90

0.35

Baseline CHADS-VASc

0.21

0.007

0.38

0.76

0.70

0.18

−0.90

0.19

Baseline CCS-SAF

−0.80

<0.001

4.30

0.006

1.20

0.09

−0.60

0.46

Baseline AFEQT

0.008

0.07

−0.69

<0.001

−0.10

<0.001

−0.05

0.25

Baseline PCS

0.01

0.07

−0.58

<0.001

−0.50

<0.001

0.21

0.01

Baseline MCS

0.009

0.27

−0.44

0.001

0.11

0.06

−0.64

<0.001

AAD at 12 months

0.33

0.15

−8.41

0.02

−3.79

0.03

−4.9

0.02

AAD in blanking period

−0.15

0.51

0.14

0.96

0.01

0.99

−3.30

0.14

Procedure type:

PVAC (platinum + gold) vs. control

0.09

0.40

−2.85

0.43

−4.14

0.01

0.64

0.76

PVAC platinum vs. control

0.16

0.49

−4.11

0.29

−4.45

0.01

0.99

PVAC gold vs. control

−0.03

0.80

−0.07

0.97

−1.69

0.14

1.12

0.46

PVAC gold vs. platinum

−0.23

0.41

3.95

0.40

1.07

0.62

2.2

0.41

Early recurrence

0.59

0.006

−5.10

0.15

−0.48

0.77

−3.44

0.09

Redo ablation

0.20

0.43

−6.10

0.21`

−6.04

0.01

−4.50

0.12

Complications within 12 months follow-up

1.20

0.003

−5.70

0.40

−5.80

0.06

4.90

0.20

Cardioversion within 12 months follow-up

0.10

0.59

−10.70

0.02

−1.04

0.64

−0.50

0.80

#Cardioversion within 12 months follow-up

0.20

0.34

−9.60

0.009

−0.90

0.50

−0.90

0.60

Recurrence

0.80

<0.001

−9.40

0.008

−4.80

0.003

−2.20

0.26

AFB h/month at 12 months <24

−1.90

<0.001

19.50

<0.001

5.50

0.03

2.08

0.50

	ΔCCS-SAF		ΔAFEQT		ΔPCS		ΔMCS
Age	−0.02	0.006	−0.1	0.36	0.04	0.52	−0.20	0.03
Sex (female)	−0.20	0.33	8.90	0.02	−0.30	0.84	1.70	0.45
No. of failed AADs	−0.07	0.95	−0.60	0.68	−0.02	0.97	−1.80	0.06
Hx HTN	−0.10	0.45	−4.70	0.19	1.30	0.41	−2.50	0.23
Hx DM	−0.18	0.62	−7.90	0.20	1.50	0.58	−1.30	0.69
LVEF	−0.10	0.78	0.10	0.52	−0.02	0.85	−0.28	0.07
LVEF < 50%	−0.02	0.96	−9.70	0.24	−3.82	0.31	1.24	0.79
Baseline AFB (h/month)	0.001	0.13	−0.01	0.06	−0.004	0.19	−0.007	0.07
Baseline CHADS₂	0.01	0.87	−2.10	0.21	0.30	0.68	−0.90	0.35
Baseline CHADS-VASc	0.21	0.007	0.38	0.76	0.70	0.18	−0.90	0.19
Baseline CCS-SAF	−0.80	<0.001	4.30	0.006	1.20	0.09	−0.60	0.46
Baseline AFEQT	0.008	0.07	−0.69	<0.001	−0.10	<0.001	−0.05	0.25
Baseline PCS	0.01	0.07	−0.58	<0.001	−0.50	<0.001	0.21	0.01
Baseline MCS	0.009	0.27	−0.44	0.001	0.11	0.06	−0.64	<0.001
AAD at 12 months	0.33	0.15	−8.41	0.02	−3.79	0.03	−4.9	0.02
AAD in blanking period	−0.15	0.51	0.14	0.96	0.01	0.99	−3.30	0.14
Procedure type:
PVAC (platinum + gold) vs. control	0.09	0.40	−2.85	0.43	−4.14	0.01	0.64	0.76
PVAC platinum vs. control	0.16	0.49	−4.11	0.29	−4.45	0.01	0.01	0.99
PVAC gold vs. control	−0.03	0.80	−0.07	0.97	−1.69	0.14	1.12	0.46
PVAC gold vs. platinum	−0.23	0.41	3.95	0.40	1.07	0.62	2.2	0.41
Early recurrence	0.59	0.006	−5.10	0.15	−0.48	0.77	−3.44	0.09
Redo ablation	0.20	0.43	−6.10	0.21`	−6.04	0.01	−4.50	0.12
Complications within 12 months follow-up	1.20	0.003	−5.70	0.40	−5.80	0.06	4.90	0.20
Cardioversion within 12 months follow-up	0.10	0.59	−10.70	0.02	−1.04	0.64	−0.50	0.80
#Cardioversion within 12 months follow-up	0.20	0.34	−9.60	0.009	−0.90	0.50	−0.90	0.60
Recurrence	0.80	<0.001	−9.40	0.008	−4.80	0.003	−2.20	0.26
AFB h/month at 12 months <24	−1.90	<0.001	19.50	<0.001	5.50	0.03	2.08	0.50

Table 3

Open in new tab

Univariate predictors of change in QOL scores post-ablation

	ΔCCS-SAF		ΔAFEQT		ΔPCS		ΔMCS
	β	P-value	β	P-value	β	P-value	β	P-value
	Unstandardized		Unstandardized		Unstandardized		Unstandardized
Age	−0.02	0.006	−0.1	0.36	0.04	0.52	−0.20	0.03
Sex (female)	−0.20	0.33	8.90	0.02	−0.30	0.84	1.70	0.45
No. of failed AADs	−0.07	0.95	−0.60	0.68	−0.02	0.97	−1.80	0.06
Hx HTN	−0.10	0.45	−4.70	0.19	1.30	0.41	−2.50	0.23
Hx DM	−0.18	0.62	−7.90	0.20	1.50	0.58	−1.30	0.69
LVEF	−0.10	0.78	0.10	0.52	−0.02	0.85	−0.28	0.07
LVEF < 50%	−0.02	0.96	−9.70	0.24	−3.82	0.31	1.24	0.79
Baseline AFB (h/month)	0.001	0.13	−0.01	0.06	−0.004	0.19	−0.007	0.07
Baseline CHADS₂	0.01	0.87	−2.10	0.21	0.30	0.68	−0.90	0.35
Baseline CHADS-VASc	0.21	0.007	0.38	0.76	0.70	0.18	−0.90	0.19
Baseline CCS-SAF	−0.80	<0.001	4.30	0.006	1.20	0.09	−0.60	0.46
Baseline AFEQT	0.008	0.07	−0.69	<0.001	−0.10	<0.001	−0.05	0.25
Baseline PCS	0.01	0.07	−0.58	<0.001	−0.50	<0.001	0.21	0.01
Baseline MCS	0.009	0.27	−0.44	0.001	0.11	0.06	−0.64	<0.001
AAD at 12 months	0.33	0.15	−8.41	0.02	−3.79	0.03	−4.9	0.02
AAD in blanking period	−0.15	0.51	0.14	0.96	0.01	0.99	−3.30	0.14
Procedure type:
PVAC (platinum + gold) vs. control	0.09	0.40	−2.85	0.43	−4.14	0.01	0.64	0.76
PVAC platinum vs. control	0.16	0.49	−4.11	0.29	−4.45	0.01	0.01	0.99
PVAC gold vs. control	−0.03	0.80	−0.07	0.97	−1.69	0.14	1.12	0.46
PVAC gold vs. platinum	−0.23	0.41	3.95	0.40	1.07	0.62	2.2	0.41
Early recurrence	0.59	0.006	−5.10	0.15	−0.48	0.77	−3.44	0.09
Redo ablation	0.20	0.43	−6.10	0.21`	−6.04	0.01	−4.50	0.12
Complications within 12 months follow-up	1.20	0.003	−5.70	0.40	−5.80	0.06	4.90	0.20
Cardioversion within 12 months follow-up	0.10	0.59	−10.70	0.02	−1.04	0.64	−0.50	0.80
#Cardioversion within 12 months follow-up	0.20	0.34	−9.60	0.009	−0.90	0.50	−0.90	0.60
Recurrence	0.80	<0.001	−9.40	0.008	−4.80	0.003	−2.20	0.26
AFB h/month at 12 months <24	−1.90	<0.001	19.50	<0.001	5.50	0.03	2.08	0.50

	ΔCCS-SAF		ΔAFEQT		ΔPCS		ΔMCS
	β	P-value	β	P-value	β	P-value	β	P-value
	Unstandardized		Unstandardized		Unstandardized		Unstandardized
Age	−0.02	0.006	−0.1	0.36	0.04	0.52	−0.20	0.03
Sex (female)	−0.20	0.33	8.90	0.02	−0.30	0.84	1.70	0.45
No. of failed AADs	−0.07	0.95	−0.60	0.68	−0.02	0.97	−1.80	0.06
Hx HTN	−0.10	0.45	−4.70	0.19	1.30	0.41	−2.50	0.23
Hx DM	−0.18	0.62	−7.90	0.20	1.50	0.58	−1.30	0.69
LVEF	−0.10	0.78	0.10	0.52	−0.02	0.85	−0.28	0.07
LVEF < 50%	−0.02	0.96	−9.70	0.24	−3.82	0.31	1.24	0.79
Baseline AFB (h/month)	0.001	0.13	−0.01	0.06	−0.004	0.19	−0.007	0.07
Baseline CHADS₂	0.01	0.87	−2.10	0.21	0.30	0.68	−0.90	0.35
Baseline CHADS-VASc	0.21	0.007	0.38	0.76	0.70	0.18	−0.90	0.19
Baseline CCS-SAF	−0.80	<0.001	4.30	0.006	1.20	0.09	−0.60	0.46
Baseline AFEQT	0.008	0.07	−0.69	<0.001	−0.10	<0.001	−0.05	0.25
Baseline PCS	0.01	0.07	−0.58	<0.001	−0.50	<0.001	0.21	0.01
Baseline MCS	0.009	0.27	−0.44	0.001	0.11	0.06	−0.64	<0.001
AAD at 12 months	0.33	0.15	−8.41	0.02	−3.79	0.03	−4.9	0.02
AAD in blanking period	−0.15	0.51	0.14	0.96	0.01	0.99	−3.30	0.14
Procedure type:
PVAC (platinum + gold) vs. control	0.09	0.40	−2.85	0.43	−4.14	0.01	0.64	0.76
PVAC platinum vs. control	0.16	0.49	−4.11	0.29	−4.45	0.01	0.01	0.99
PVAC gold vs. control	−0.03	0.80	−0.07	0.97	−1.69	0.14	1.12	0.46
PVAC gold vs. platinum	−0.23	0.41	3.95	0.40	1.07	0.62	2.2	0.41
Early recurrence	0.59	0.006	−5.10	0.15	−0.48	0.77	−3.44	0.09
Redo ablation	0.20	0.43	−6.10	0.21`	−6.04	0.01	−4.50	0.12
Complications within 12 months follow-up	1.20	0.003	−5.70	0.40	−5.80	0.06	4.90	0.20
Cardioversion within 12 months follow-up	0.10	0.59	−10.70	0.02	−1.04	0.64	−0.50	0.80
#Cardioversion within 12 months follow-up	0.20	0.34	−9.60	0.009	−0.90	0.50	−0.90	0.60
Recurrence	0.80	<0.001	−9.40	0.008	−4.80	0.003	−2.20	0.26
AFB h/month at 12 months <24	−1.90	<0.001	19.50	<0.001	5.50	0.03	2.08	0.50

AAD, antiarrhythmic drugs; AFB, atrial fibrillation burden; AFEQT, Atrial Fibrillation Effect on QualiTy-of-life; CCS_SAF: Canadian Cardiovascular Society Severity in Atrial Fibrillation; DM, diabetes mellitus; HTN, hypertension; Hx, history; LVEF, left ventricular ejection fraction; MCS, mental component score; PCS, physical component score; QOL, quality of life. All changes in QOL represent change from baseline to 12 months. The unstandardized definition shows the change in CCS SAF, AFEQT, PCS and MCS for 1 unit change in the predicting variable.

This Feature Is Available To Subscribers Only